AFT Pharmaceuticals Limited (AFT) H2 2026 earnings summary

Executive summary

• Achieved revenue of NZD 254.7 million (or $254.7M) for FY26, up 22% year-over-year, with a five-year CAGR of 17.6% and double-digit growth across all regions.

• Operating profit reached NZD 24.4 million ($24.4M), exceeding guidance, and a record dividend of 2.5cps was declared, up 39%.

• Strong growth in Australia, New Zealand, and Asia, with international expansion now reaching 87 countries.

• Significant investments in R&D, international business hubs, and product portfolio diversification, with 8 patented and 24+ off-patent injectables in development.

• Continued disciplined global expansion, including new launches and licensing agreements in Europe, North America, South Africa, and Asia.

Financial highlights

• Revenue rose 22% to NZD 254.7 million ($254.7M); product sales and royalties up 21% to $251.6M.

• Operating profit was NZD 24.4 million ($24.4M), up from NZD 17.6 million ($17.6M) year-over-year.

• Net profit after tax increased 24% to NZD 14.1 million ($14.1M).

• EBITDA rose to NZD 28.8 million ($28.8M), with EBITDA margin at 11.3%.

• Gross margin on product sales and royalties slightly declined to 42.7% (from 43.9%).

Outlook and guidance

• Targeting at least NZD 300 million ($300M+) in sales for FY27, with operating profit guidance of NZD 28–32 million ($28M–$32M).

• Continued expansion in Australasian and international markets, with UK and South Africa expected to contribute positively.

• Ongoing investment in R&D and licensing to drive future growth, with R&D spend projected at NZD 25 million in 2027.